A multicenter, single-arm clinical trial of an assertive case management intervention for preventing suicide reattempts at psychiatric hospitals in Japan: ACTION-JP study Authors: Ryutaro Ishibashi, Naohiro Yonemoto, Yoshinori Cho, Naoya Sugiyama, Yoshiki Kishi, Kiyoshi Fujita, Masayuki Morikawa, Masaru Tateno, Yoko Kawahara, Kotaro Otsuka, Tomoaki Sano, Kosuke Komata, Chiaki Kawanishi Published: 2025 ABSTRACT BackgroundThe post-discharge period following psychiatric hospitalization is a high-risk period for suicide attempts. This risk is substantially higher for patients admitted for suicidal behavior. Despite the urgent need for effective countermeasures, evidence-based interventions specifically designed to prevent suicide reattempts in this high-risk population remain limited. Although assertive case management is recognized as an effective intervention, its feasibility, safety, and efficacy for patients in psychiatric hospitals remain uninvestigated. The ACTION-JP study aims to evaluate the feasibility, safety, and efficacy of such an intervention adapted for patients in Japan admitted to psychiatric hospitals following a suicide attempt.MethodsThe ACTION-JP study is a multicenter, single-arm clinical trial. A total of 220 adult patients admitted to participating psychiatric hospitals following a suicide attempt will be enrolled. The intervention comprises two main components: a psychoeducation program conducted during hospitalization and an 18-month structured assertive case management follow-up. The primary outcome is the change from baseline in the Columbia-Suicide Severity Rating Scale total score at the 6-month follow-up. Secondary outcomes include the incidence of suicide reattempts and self-harm, as well as changes in Beck Depression Inventory-II and Global Assessment of Functioning Scale scores.DiscussionThis study protocol describes the essential first step in developing an evidence-based suicide prevention strategy for psychiatric inpatients. This study will provide important data on the intervention’s feasibility, safety, and efficacy. The findings are expected to offer important insights into the potential effectiveness of assertive case management for reducing suicide risk post-discharge. The successful implementation of this study will provide the necessary basis for designing a future large-scale randomized controlled trial that may help to establish a new standard of care in psychiatric hospitals.Trial registrationThis trial was registered on the University Hospital Medical Information Network clinical trials registry: UMIN000057009 (Date of registration: April 1, 2025) and the Japan Registry for Clinical Trials: jRCT1010250041 (Date of registration: October 20, 2025).Supplementary informationThe online version contains supplementary material available at 10.1186/s12888-025-07554-0. Background The period of post-discharge following psychiatric hospitalization represents a high-risk period for suicide attempts [1]. This risk is considerably higher for patients admitted to psychiatric hospitals because of suicidal behavior [2]. Preventing post-discharge suicide reattempts is therefore very important, though it remains a formidable clinical challenge. Although suicide prevention interventions for psychiatric inpatients are essential, their effectiveness remains controversial. Psychosocial interventions aimed at reducing the risk of suicide and self-harm (i.e., intentional self-poisoning or injury, irrespective of the apparent purpose [3]), such as cognitive behavioral therapy and dialectical behavioral therapy, have been widely implemented. However, a recent systematic review and meta-analysis found that these general psychosocial interventions for inpatient settings do not substantially reduce suicidal ideation or depression compared with treatment as usual [4]. Moreover, even interventions that target suicide risk have shown inconsistent results. For example, a recent study of a brief, four-session cognitive behavioral therapy program for inpatients experiencing a suicide crisis demonstrated notable variation in beneficial outcomes: although it successfully reduced behavioral outcomes such as suicide attempts and psychiatric rehospitalizations, it failed to produce a significant improvement in suicidal ideation [5]. Taken together, these findings demonstrate that evidence-based interventions specifically designed to reduce post-discharge suicide reattempt risk for psychiatric inpatients remain limited and lack strong recommendations. Given the limitations of current psychosocial treatments, exploring alternative strategies is essential. One promising approach is active contact and follow-up, which has demonstrated efficacy in preventing suicide reattempts [6]. A notable example is the ACTION-J study, which confirmed the efficacy of assertive case management in preventing suicide reattempts among suicide attempters admitted to emergency departments [7]. Furthermore, the Post-ACTION-J study confirmed that this assertive case management intervention program is feasible for implementation in real-world clinical settings and effective in reducing depressive symptoms and suicidal ideation following its social implementation [8]. Despite this promising evidence, the safety and efficacy of this intervention for psychiatric inpatients remain uninvestigated. The present study aims to evaluate the feasibility, safety, and efficacy of an assertive case management intervention for patients admitted to psychiatric hospitals following a suicide attempt. Methods Primary hypothesis Our primary hypothesis is that assertive case management will be feasible, safe, and effective in reducing suicide-related behavior for patients admitted to psychiatric hospitals following a suicide attempt. Study design The ACTION-JP is a multicenter, single-arm clinical trial designed to evaluate the feasibility, safety, and efficacy of an assertive case management intervention among patients in Japan admitted to psychiatric hospitals following a suicide attempt. The study design is shown in Fig. 1.Fig. 1Study flowchart Study flowchart Study participants Eligible participants are patients admitted to psychiatric hospitals because of a suicide attempt. This includes patients transferred to psychiatric hospitals within 1 month of their initial presentation to an emergency department for a suicide attempt. Inclusion criteria Aged 18 years or older.Diagnosed with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I psychiatric disorder based on clinical evaluation.Confirmed suicidal intent at the time of the index suicide attempt, as assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS).Enrollment in the study within 1 month of the index suicide attempt.Ability to understand the study procedures and provide written informed consent.Ability to understand and communicate in Japanese.Ability to participate in scheduled intervention sessions (psychoeducation and assertive case management) during hospitalization.Ability to attend scheduled follow-up visits at participating facilities for evaluations and assertive case management sessions.No previous participation in the current study. Aged 18 years or older. Aged 18 years or older. Diagnosed with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I psychiatric disorder based on clinical evaluation. Diagnosed with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I psychiatric disorder based on clinical evaluation. Confirmed suicidal intent at the time of the index suicide attempt, as assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). Confirmed suicidal intent at the time of the index suicide attempt, as assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). Enrollment in the study within 1 month of the index suicide attempt. Enrollment in the study within 1 month of the index suicide attempt. Ability to understand the study procedures and provide written informed consent. Ability to understand the study procedures and provide written informed consent. Ability to understand and communicate in Japanese. Ability to understand and communicate in Japanese. Ability to participate in scheduled intervention sessions (psychoeducation and assertive case management) during hospitalization. Ability to participate in scheduled intervention sessions (psychoeducation and assertive case management) during hospitalization. Ability to attend scheduled follow-up visits at participating facilities for evaluations and assertive case management sessions. Ability to attend scheduled follow-up visits at participating facilities for evaluations and assertive case management sessions. No previous participation in the current study. No previous participation in the current study. Exclusion criteria Absence of a DSM-IV Axis I psychiatric diagnosis.A history of previous exposure to the assertive case management intervention program used in the current study (the ACTION-JP study). Absence of a DSM-IV Axis I psychiatric diagnosis. Absence of a DSM-IV Axis I psychiatric diagnosis. A history of previous exposure to the assertive case management intervention program used in the current study (the ACTION-JP study). A history of previous exposure to the assertive case management intervention program used in the current study (the ACTION-JP study). Sample size The total sample size is 220 participants. The required sample size was calculated using the following rationale. For the primary outcome, the change from baseline in the C-SSRS total score, we hypothesized a mean change of 2 with a standard deviation of 10. This estimate was informed by findings from the Post-ACTION-J study, and accounted for potential differences in clinical settings. Given these assumptions, the required number of participants was calculated to be 199. Therefore, the sample size was set at 220, considering potential loss to follow-up and missing data. Informed consent Participants will be recruited from patients admitted to the psychiatric hospitals of participating facilities following a suicide attempt. Eligible patients will meet predefined inclusion criteria and provide written informed consent. Enrollment Participant enrollment will be conducted in accordance with the protocol summarized in Fig. 1. Potential study participants will receive psychiatric examinations to obtain clinical information and establish a psychiatric diagnosis according to the DSM-IV criteria. Suicidal intent will be assessed using the C-SSRS. The investigator will confirm that the patient is not a previous participant in this study. Eligibility for study participation will be determined using predefined inclusion and exclusion criteria. Subsequently, written informed consent will be obtained from eligible patients. Participating facilities This study will be conducted at facilities meeting the following criteria:The facility must be a psychiatric hospital in Japan.The clinical team must include a psychiatrist with appropriate training and at least one of the following professionals: nurse, occupational therapist, clinical psychologist, or mental health social worker.The facility must have a substantial clinical track record in the treatment of patients who have attempted suicide, maintain close collaboration with emergency medical facilities, and be able to provide psychiatric intervention immediately following a suicide attempt.The facility must be able to provide outpatient care to patients discharged from inpatient treatment for a suicide attempt or self-harm. The facility must be a psychiatric hospital in Japan. The facility must be a psychiatric hospital in Japan. The clinical team must include a psychiatrist with appropriate training and at least one of the following professionals: nurse, occupational therapist, clinical psychologist, or mental health social worker. The clinical team must include a psychiatrist with appropriate training and at least one of the following professionals: nurse, occupational therapist, clinical psychologist, or mental health social worker. The facility must have a substantial clinical track record in the treatment of patients who have attempted suicide, maintain close collaboration with emergency medical facilities, and be able to provide psychiatric intervention immediately following a suicide attempt. The facility must have a substantial clinical track record in the treatment of patients who have attempted suicide, maintain close collaboration with emergency medical facilities, and be able to provide psychiatric intervention immediately following a suicide attempt. The facility must be able to provide outpatient care to patients discharged from inpatient treatment for a suicide attempt or self-harm. The facility must be able to provide outpatient care to patients discharged from inpatient treatment for a suicide attempt or self-harm. All participating researchers must attend a training program. The program will cover suicide prevention (including epidemiology, risk factors, psychology, prevention, intervention, and postvention), how to use an assessment and planning form to successfully conduct assertive case management, and how to conduct the psychoeducation program and psychiatric evaluations using psychological measures (these elements of training include role-playing and group exercises using patient simulations). Intervention The intervention comprises two main components: a psychoeducation program and scheduled assertive case management follow-up. The psychoeducation program will be delivered shortly after participant enrollment. This program is designed to educate participants about the psychological processes leading to suicide, risk factors for suicide, and the association between suicide and mental disorders. It will also cover stress coping strategies, the benefits of psychosocial support, and available social resources. The psychoeducation will be delivered using an educational manual that will be standardized to ensure consistent implementation across all participating sites. The assertive case management follow-up will be conducted at study registration; at weeks 1, 4, 8, and 12; and at months 6, 12, and 18 post-registration. Case management involves regular assessment and planning focused on problem resolution. During each session, assessments will be performed of the participant’s suicide risk, current living situation, facilitation of access to psychiatric and physical healthcare, and utilization of social resources. Based on these assessments, individualized problem-solving plans will be developed and reviewed. Assertive case management activities The case management follow-up will encompass the following activities:Periodic follow-up with participants.Collection of information about each participant’s current treatment status and any social problems that might disrupt their treatment adherence.Encouragement of participants to adhere to psychiatric treatment.Coordination of appointments with psychiatrists and primary care physicians.Re-engagement efforts for participants who have discontinued psychiatric treatment.Referral to and coordination of social resources and private support organizations to accommodate the individual needs of participants.Provision of psychoeducation and information to family members. Periodic follow-up with participants. Periodic follow-up with participants. Collection of information about each participant’s current treatment status and any social problems that might disrupt their treatment adherence. Collection of information about each participant’s current treatment status and any social problems that might disrupt their treatment adherence. Encouragement of participants to adhere to psychiatric treatment. Encouragement of participants to adhere to psychiatric treatment. Coordination of appointments with psychiatrists and primary care physicians. Coordination of appointments with psychiatrists and primary care physicians. Re-engagement efforts for participants who have discontinued psychiatric treatment. Re-engagement efforts for participants who have discontinued psychiatric treatment. Referral to and coordination of social resources and private support organizations to accommodate the individual needs of participants. Referral to and coordination of social resources and private support organizations to accommodate the individual needs of participants. Provision of psychoeducation and information to family members. Provision of psychoeducation and information to family members. Case management follow-up schedule and its flexibility The case management follow-up scheduled for the first week should ideally be conducted within 2 days of the target date. A 1-week window is permitted for follow-up scheduled at weeks 4, 8, and 12. The 6-month follow-up may be performed within a 2-week time frame, and subsequent follow-up allows for a 1-month window relative to the scheduled date. Participants will be notified before scheduled access dates via email, telephone, or postal mail. The assertive case management intervention will be conducted using face-to-face dialogue at participating facilities. Oversight and coordination Case managers will engage in routine case conferences with psychiatrists. To ensure protocol adherence and effective intervention delivery, the study management office and the intervention program committee will conduct periodic meetings with the study group, perform site visits to participating facilities, and meet with case managers as needed. Data collection The data collection procedures will follow the schedule detailed in Table 1.Table 1Task scheduleAfter registrationDuring admission1week4weeks8weeks12weeks6months12months18monthsInformed consent, and registration◎Psychiatric diagnosis◎Psychoeducation◎Scheduled assertive case management follow-up◎◎◎◎◎◎◎◎Psychological measures◎◎◎◎◎◎Actions to critical situationsDuring the study as occasions requireReports of a serious adverse eventPrompt report to the director of the hospital and the study group management office as occasions require Table 1Task scheduleAfter registrationDuring admission1week4weeks8weeks12weeks6months12months18monthsInformed consent, and registration◎Psychiatric diagnosis◎Psychoeducation◎Scheduled assertive case management follow-up◎◎◎◎◎◎◎◎Psychological measures◎◎◎◎◎◎Actions to critical situationsDuring the study as occasions requireReports of a serious adverse eventPrompt report to the director of the hospital and the study group management office as occasions require Task schedule The data management center will consolidate the collected data and periodically deliver it to the study management office and the chairperson of the event review committee, adhering to established data management procedures. The study management office and the chairperson of the event review committee will convene regular event review meetings to evaluate and assess the details of each reported event based on the provided materials. Specific details regarding event classification and management are outlined in the event definitions and event review procedures. Basic patient information The patient information collected includes initials, age, sex, cohabiting individuals, marital status, education, employment status, family medical history (including psychiatric disorders), history of medical treatment, and alcohol consumption habits. Psychiatric evaluation Detailed information about the index suicide attempt leading to enrollment in the study will be collected. A comprehensive psychiatric history will be obtained, including previous psychiatric care (hospitalizations, outpatient treatment) and all previous psychiatric diagnoses. These diagnoses will be confirmed by a psychiatrist according to the DSM-IV criteria. The psychiatrist must have completed the training program developed by the study management committee. Case management records These data will comprise presence and severity of suicidal ideation and risk, current psychosocial problems, availability of people or social resources the patient can consult regularly, information about psychiatric treatment, and information about any medical treatment. Psychological measures The C-SSRS is a validated and standardized instrument. This scale will be administered to comprehensively assess the presence and severity of suicidal behavior and ideation [9]. The Beck Depression Inventory-II (BDI-II), a widely used and reliable self-report questionnaire, will be used to measure the severity of depressive symptoms [10]. The Global Assessment of Functioning (GAF) Scale will be used to provide a subjective, overall rating of participants’ social, occupational, and psychological functioning at baseline and throughout the study period [11]. Data management and security The data management center is responsible for the centralized management of data for the registered cases. It maintains a comprehensive database that includes the basic information for all participants, case management records, and event reporting. To ensure data integrity, the center performs regular data backups. Meticulous security measures are implemented to protect confidentiality; access to the database is restricted by password authentication to prevent unauthorized access. Furthermore, all computers used for data management undergo regular updates, and antivirus software is consistently updated with the latest version. Data retention The principal investigator at each participating facility will retain all datasets (e.g., case sheets) created for the study, even after study completion. The study management office and the data management center will also retain any newly created datasets or materials generated during the implementation of the study. All participants will comply with the Act on the Protection of Personal Information and will store research datasets and materials according to the procedures outlined in the data storage standard operating procedure. Retention period The retention period will adhere to the Sapporo Medical University guidelines for preventing research misconduct, which specify a storage period of 10 years following the publication of the relevant papers. Study phases Study period: April 2025 through June 2028 Enrollment period: April 2025 through June 30, 2026 Follow-up period: April 2025 through December 2027 Outcomes Primary outcome measure The primary outcome is the change from baseline in the total score on the C-SSRS at the 6-month follow-up. Secondary outcome measures Secondary outcomes will be assessed at 1, 3, 6, 12, and 18 months post-registration. These are as follows:Incidence of key events, including all-cause mortality, suicide, first recurrent suicide attempt, and self-harm. These will be reported as proportions and person-year rates.Frequency of suicide attempts and self-harm.Continuity of psychiatric care.Change from baseline in C-SSRS scores at each follow-up point.Change from baseline in BDI-II scores.Change from baseline in GAF Scale scores. Incidence of key events, including all-cause mortality, suicide, first recurrent suicide attempt, and self-harm. These will be reported as proportions and person-year rates. Incidence of key events, including all-cause mortality, suicide, first recurrent suicide attempt, and self-harm. These will be reported as proportions and person-year rates. Frequency of suicide attempts and self-harm. Frequency of suicide attempts and self-harm. Continuity of psychiatric care. Continuity of psychiatric care. Change from baseline in C-SSRS scores at each follow-up point. Change from baseline in C-SSRS scores at each follow-up point. Change from baseline in BDI-II scores. Change from baseline in BDI-II scores. Change from baseline in GAF Scale scores. Change from baseline in GAF Scale scores. Assessment schedule All enrolled participants will undergo standardized assessments at baseline (at the time of registration, following provision of written informed consent) and at 1, 3, 6, 12, and 18 months post-registration. A 1-month window is permitted for each scheduled assessment. Event monitoring and reporting Throughout the study, the following events will be monitored and systematically documented:Suicide reattemptsDeath (from any cause)Self-harmAny other adverse events, regardless of causality. Suicide reattempts Suicide reattempts Death (from any cause) Death (from any cause) Self-harm Self-harm Any other adverse events, regardless of causality. Any other adverse events, regardless of causality. Assessment procedures and data collection Psychiatric evaluations will be conducted by trained and certified evaluators (e.g., psychiatrists, clinical psychologists, mental health social workers). Evaluators will not act as case managers for any participant. Evaluations will be conducted via in-person follow-up at participating facilities using a standardized form. Participants will be notified by email or telephone of their scheduled evaluation 7 days in advance. At the conclusion of each assessment, the subsequent evaluation will be scheduled and the date confirmed with the participant. Upon identification of an event, on-site research staff will document the details on an event review sheet and confirm them with the site investigator. The information will then be entered into a web-based data entry system. In the event of a serious adverse event, the on-site research coordinator will promptly notify the hospital director and fax the event review sheet directly to the study management office. Any required clarifications will be resolved through consultation between the on-site staff and the study management office. Evaluation of events The event review committee will adjudicate events related to primary and secondary outcomes. This committee will define standardized evaluation criteria, which will be documented with the event definitions and event review procedures, to ensure consistent adjudication. Safety management In the event of a serious adverse event or imminent risk of suicide, research staff at the participating facilities will take all necessary and appropriate actions to ensure participant safety. On-site research staff will immediately contact the hospital’s on-site research coordinator, who will promptly submit a report to the institution director and the study management office. As the national medical payment system in Japan has implemented this assertive case management intervention, we do not anticipate any negative health effects from the study itself. Any participant health concerns that arise will be handled through the normal protocols of medical care provision. Statistical analyses Primary analysis The primary objective of this study is to examine the efficacy of the assertive case management intervention, and to assess the effect of the intervention on C-SSRS scores. The intention-to-treat population will include all participants enrolled in the study to test the efficacy of the intervention. The safety analysis population will consist of all participants who received the intervention. We will calculate the mean difference in C-SSRS scores between baseline and 6 months, along with its corresponding 95% confidence interval (CI). A one-sample t-test will be used, with a pre-specified two-tailed alpha level of 0.05. Secondary analysis To provide supporting information for the primary analysis, secondary outcome measures will be analyzed. Subgroup analyses will be conducted for both primary and secondary outcomes, stratified by site, sex, age (younger than 40 years vs 40 years or older), and history of suicide attempts. The analysis of secondary outcome measures will be performed as follows. For variables for which differences in means are assessed, the mean difference and its 95% CI and p-value will be reported. For continuous variables with no baseline measurement, the mean and its 95% CI and p-value from a one-sample t-test will be reported. For binary variables, the proportion and its 95% CI and the p-value from a one-sample test for proportions will be reported. For time-to-event data, survival curves will be described using the Kaplan–Meier method, and a one-sample log-rank test will be performed. Given the exploratory nature of these secondary statistical analyses, no adjustments for multiple comparisons will be made. To provide information about feasibility, adherence to the intervention will be analyzed. Additionally, to provide safety information, adverse events will be analyzed. Study monitoring The study monitoring plan is summarized in Fig. 2.Fig. 2Study monitoring and management structure Study monitoring and management structure Periodic monitoring Participating facilities will submit monitoring reports, including the information summarized below, to the data management center every 6 months. The data management center will subsequently forward these reports to the study investigator. The monitoring reports will contain the following information: 1) study progress, including enrollment figures; 2) the status of psychiatric evaluation implementation; 3) data on event occurrence; 4) data on adverse event occurrence; and 5) other pertinent information, such as the presence of any undesirable issues or events. Protocol amendments If any safety issues arise from the periodic monitoring, or any serious adverse events or other events that may affect the continuation of the study occur, the principal investigator will promptly convene a study steering committee meeting to discuss potential modifications to the study protocol. If protocol modification is deemed necessary after discussion, the principal investigator will revise the protocol. The study management office will immediately distribute the revised protocol to all the on-site research staff through the on-site research coordinator. The on-site research coordinator will submit the revised study protocol to the on-site research ethics committee at each participating facility. The study will resume only after the revised protocol has been approved by each ethics committee. Discussion This article describes the protocol (Version 1; March 2025) for the ACTION-JP study, a multicenter, single-arm study designed to evaluate an assertive case management intervention for suicide attempters admitted to psychiatric hospitals in Japan. Although the post-discharge period from psychiatric hospitalization is known to be a period of markedly elevated suicide risk, few evidence-based interventions have been specifically developed and tested for this population. This study directly addresses this important gap in suicide prevention. The primary aim of this study is to establish a rigorous framework for investigating the feasibility, safety, and efficacy of this intervention in psychiatric hospitals. The rationale for the chosen study design and intervention is firmly grounded in evidence from previous research and pragmatic considerations. The feasibility data collected in this study will be used to plan a future randomized controlled trial. These design elements will ensure that the data generated from this study are of high quality and suitable for informing future research. In conclusion, this study protocol describes a methodologically sound, pragmatic, and necessary first step in developing an evidence-based suicide prevention strategy for patients discharged from psychiatric hospitals. The successful implementation of this study is expected to provide essential data to guide future research and ultimately facilitate the establishment of a new standard of suicide prevention treatment in psychiatric hospitals. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1